From the Research
The Cmax (maximum plasma concentration) for Vyvanse (lisdexamfetamine) 70 mg is approximately 80-90 ng/mL, typically reached about 3-4 hours after oral administration. This represents the peak blood concentration of the active metabolite dextroamphetamine, not the parent compound lisdexamfetamine. Vyvanse is a prodrug that requires enzymatic conversion in the bloodstream to become active, which contributes to its gradual onset and extended duration of action. This pharmacokinetic profile helps reduce abuse potential compared to immediate-release stimulants. Individual factors such as body weight, metabolism, liver function, and concurrent medications can influence the actual Cmax achieved in a specific person. The gradual rise to peak concentration helps minimize the euphoric effects associated with rapid increases in amphetamine levels while maintaining therapeutic efficacy for ADHD symptom control throughout the day. According to the most recent study 1, lisdexamfetamine dimesylate is a stimulant prodrug with low abuse and diversion potential that is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. Some key points to consider when prescribing Vyvanse include:
- The most commonly exhibited side effects were appetite suppression, weight loss, headache, and insomnia 1
- In comparison to placebo, Vyvanse significantly improved ADHD symptoms and overall quality of life in children and adolescents 1
- In comparison to atomoxetine, Vyvanse showed statistically significant improvements in inattention, impulsivity, and activities of daily living 2
- Patients have seen statistically significant improvements in their ADHD symptomatology in the classroom environment, health-related quality of life, and their overall behavior in comparison to placebo, atomoxetine, and OROS-MPH 1